Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
University of Washington Canary Foundation Early Detection Research Network |
---|---|
Information provided by: | University of Washington |
ClinicalTrials.gov Identifier: | NCT00756665 |
The Prostate Active Surveillance Study (PASS) is a research study for men who have chosen active surveillance as a management plan for their prostate cancer. Active surveillance is defined as close monitoring of prostate cancer with the offer of treatment if there are changes in test results. This study seeks to discover markers that will identify cancers that are more aggressive from those tumors that grow slowly.
Condition |
---|
Prostatic Neoplasms |
Study Type: | Observational |
Study Design: | Cohort, Prospective |
Official Title: | Canary Prostate Active Surveillance Study |
serum, plasma, white cells, DNA, urine, prostate tissue
Estimated Enrollment: | 500 |
Study Start Date: | July 2008 |
Estimated Primary Completion Date: | July 2018 (Final data collection date for primary outcome measure) |
This is a multi-center, prospective active surveillance study with selective intervention in patients with previously untreated, clinically localized prostate cancer at diagnosis. Candidates are assessed based on an extended core biopsy, serum PSA (including PSA kinetics, if available), digital rectal examination (DRE), and assessment of cancer grade and extent.
Active surveillance is defined as serial PSA measurements and prostate examination with routine prostate biopsy and therapeutic intervention considered at the time one or more of the following:
The objectives of the study are as follows:
Primary Objective
Secondary Objectives
Ages Eligible for Study: | 21 Years and older |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Urology Clinic
Inclusion Criteria:
Prostate biopsy requirements:
Exclusion Criteria:
United States, California | |
Stanford University | Recruiting |
Stanford, California, United States, 94305 | |
Contact: Michelle Ferrari, RN 650-725-5543 mferrari@stanford.edu | |
Principal Investigator: James D. Brooks, MD | |
University of California, San Francisco | Recruiting |
San Francisco, California, United States, 94143 | |
Contact: Imelda Tenggara-Hunter 415-353-7348 itenggara@urology.ucsf.edu | |
Principal Investigator: Peter R. Carroll, MD | |
United States, Texas | |
University of Texas Health Science Center, San Antonio | Recruiting |
San Antonio, Texas, United States, 78229 | |
Contact: Linda Hernandez, BSN, RN 210-450-1741 hernandezmh@uthscsa.edu | |
Principal Investigator: Ian M. Thompson, MD | |
United States, Washington | |
University of Washington | Recruiting |
Seattle, Washington, United States, 98195 | |
Contact: Sharon Downing, RN 206-598-0850 sdowning@u.washington.edu | |
Principal Investigator: Daniel W. Lin, MD | |
Canada, British Columbia | |
University of British Columbia | Recruiting |
Vancouver, British Columbia, Canada, V5Z 1M9 | |
Contact: Jonathan Ma 604-875-4111 ext 66557 jonathan.ma@vch.ca | |
Principal Investigator: Martin E. Gleave, MD |
Principal Investigator: | Daniel W. Lin, MD | University of Washington |
Principal Investigator: | James D. Brooks, MD | Stanford University |
Principal Investigator: | Martin E. Gleave, MD | University of British Columbia |
Principal Investigator: | Ian M. Thompson, MD | University of Texas Health Science Center, San Antonio |
Principal Investigator: | Peter R. Carroll, MD | University of California, San Francisco |
Responsible Party: | University of Washington ( Daniel W. Lin ) |
Study ID Numbers: | 33567-V |
Study First Received: | September 18, 2008 |
Last Updated: | April 28, 2009 |
ClinicalTrials.gov Identifier: | NCT00756665 History of Changes |
Health Authority: | United States: Institutional Review Board; Canada: Ethics Review Committee |
prostate cancer |
Prostatic Diseases Genital Neoplasms, Male Urogenital Neoplasms Genital Diseases, Male Prostatic Neoplasms |
Neoplasms Neoplasms by Site Prostatic Diseases Genital Neoplasms, Male |
Urogenital Neoplasms Genital Diseases, Male Prostatic Neoplasms |